| Literature DB >> 32102185 |
Daniel Ziental1, Beata Czarczynska-Goslinska2, Dariusz T Mlynarczyk3, Arleta Glowacka-Sobotta4, Beata Stanisz5, Tomasz Goslinski3, Lukasz Sobotta1.
Abstract
Metallic and metal oxide nanoparticles (NPs), including titanium dioxide NPs, among polymeric NPs, liposomes, micelles, quantum dots, dendrimers, or fullerenes, are becoming more and more important due to their potential use in novel medical therapies. Titanium dioxide (titanium(IV) oxide, titania, TiO2) is an inorganic compound that owes its recent rise in scientific interest to photoactivity. After the illumination in aqueous media with UV light, TiO2 produces an array of reactive oxygen species (ROS). The capability to produce ROS and thus induce cell death has found application in the photodynamic therapy (PDT) for the treatment of a wide range of maladies, from psoriasis to cancer. Titanium dioxide NPs were studied as photosensitizing agents in the treatment of malignant tumors as well as in photodynamic inactivation of antibiotic-resistant bacteria. Both TiO2 NPs themselves, as well as their composites and combinations with other molecules or biomolecules, can be successfully used as photosensitizers in PDT. Moreover, various organic compounds can be grafted on TiO2 nanoparticles, leading to hybrid materials. These nanostructures can reveal increased light absorption, allowing their further use in targeted therapy in medicine. In order to improve efficient anticancer and antimicrobial therapies, many approaches utilizing titanium dioxide were tested. Results of selected studies presenting the scope of potential uses are discussed in this review.Entities:
Keywords: composites; nanoparticles; photodynamic therapy; photosensitizer; titanium dioxide
Year: 2020 PMID: 32102185 PMCID: PMC7075317 DOI: 10.3390/nano10020387
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Current applications and potential future use of TiO2. PDT, photodynamic therapy; PACT, antimicrobial photodynamic therapy; DSSC, dye-sensitized solar cell.
Figure 2The spectrum of possible TiO2 nanoparticles modification for medicinal purposes.
Figure 3Simplified mechanism of reactive oxygen species generation by TiO2 (based on [37]).
Synthesis, physicochemical characteristics, and medical applications of selected TiO2 nanoparticles (NPs) combined with photosensitizers.
| Ref. | Shape of NPs (Characteristics) | Photosensitizer | Method of Synthesis | Medical/Biological Use |
|---|---|---|---|---|
| [ | P25 TiO2 (75% anatase and 25% rutile, size 25 nm) | 5,10,15,20-tetrakis(2,6-difluorosulfonylophenyl)porphyrin and its zinc(II) complex | commercial distribution | PACT against |
| [ | N-TiO2-NH2 (size: 20–30 nm) | Aluminum(III) phthalocyanine chloride tetrasulfonate | N-doping by calcination of commercially available anatase TiO2 NPs in ammonia atmosphere | PDT against cancer (HeLa and KB cell lines) |
| [ | N-TiO2-NH2 (size: 20–30 nm) | Aluminum(III) phthalocyanine chloride tetrasulfonate | N-doping by calcination of commercially available anatase TiO2 NPs in ammonia atmosphere | PDT against cancer (HeLa cell line) |
| [ | anatase (size: 23 nm spheres) | subphthalocyanine derivatives | from TiCl4 and benzyl alcohol; macrocycle deposition overnight in THF | PDT against breast and cervical tumors |
| [ | anatase (23 nm spheres) | Zinc(II) phthalocyanine derivatives | from TiCl4 and benzyl alcohol; macrocycle deposition overnight in THF | PACT against: |
| [ | anatase (23 nm spheres) | Subphthalocyanine derivative | from TiCl4 and benzyl alcohol; macrocycle deposition overnight in THF | PACT against |
| [ | anatase (size—25 nm) | Zinc(II) tetrakis(3-dodecylpyridyloxy)phthalocyanine (mixture of isomers) | deposition in pyridine/ethanol mixture | PACT against MRSA, |
| [ | no data presented | Zinc(II) phthalocyanine | sol-gel method | PACT against |
| [ | anatase/rutile film (600 nm in film thickness, 100 nm grain size) | Copper tetracarboxyphthalocyanines (mixture of isomers) | anodization | PACT against MRSA |
| [ | TiO2 nanowhiskers (size < 100 nm) | tetrasulphonatophenyl porphyrin | undefined | PDT and bioimaging of rheumatoid arthritis |
| [ | TiO2 nanowhiskers | tetrasulphonatophenyl porphyrin | undefined; deposition in water | PDT of diabetes mellitus |
| [ | P25 TiO2 (75% anatase and 25% rutile, size—21 nm) | Chlorin e6 | silylation with or without PEGylation | PDT against glioblastoma cell |
| [ | no data (size—100 nm) | methylene blue used in mixture but without grafting the NPs | commercial distribution | PACT against: |
THF—tetrahydrofuran; NPs—nanoparticles.
Figure 4Aluminum tetrasulfonatedphthalocyanine chloride linked to nitrogen-doped anatase TiO2 nanoparticles by electrostatic interactions (based on [58]).
Figure 5Selected photosensitizers combined with titanium dioxide nanoparticles; 5,10,15,20-tetrakis(2,6-difluoro-3-sulfophenyl)porphyrin (FTSPP), Chlorin e6 (Ce6), methylene blue (MB).
Figure 6Simplified mechanism of titanium(IV) oxide as drug delivery vehicle.
Synthesis, physicochemical characteristics, and medical applications of selected TiO2 NPs in combination with doxorubicin.
| Ref. | Shape of Nanoparticles (Characteristics) | Method of Synthesis | Medical/Biological Use |
|---|---|---|---|
| [ | ZnPc@TiO2_CHCl3 (20 nm) | NPs—commercially; nanotubes—from titanium(IV) isopropoxide in a sol-gel method followed by hydrothermal treatment; deposition of ZnPc in CHCl3, THF or 1:1 | PDT, bioimaging and doxorubicin delivery (tested on HeLa cells) |
| [ | UCNPs@SiO2@TiO2 (TiO2 shell thickness—5–6 nm) | TiO2 was grown on UCNPs@SiO2-NH2 NPs from titanium diisopropoxide bis(acetylacetonate); further hydrothermal treatment yielded crystalline structure | PDT in cancer treatment mixed with doxorubicin (tested on HeLa cells) |
| [ | diamond-shaped mesoporous TiO2 (220 nm in width, 250 nm in length, 40 nm thick, pore size—4.1 nm) | from Ti(IV) isopropoxide at 28 °C, followed by silylation and PEGylation | pH-responsive drug delivery vehicles for cancer therapy |
| [ | TiO2 nanowhiskers (width 80 nm, length range—200–5000 nm) | K2CO3 with TiO2 heated at 810 °C, soaked in distilled water for about 7 days, dried, and calcinated | PDT with daunorubicin delivery against hepatocarcinoma cells |
| [ | 0.3 µm TiO2 nanotube array (single nanotube diameter—90 nm) | growth of TiO2 nanotubes in a glycerol/water/NH4F mixture, then annealing to form anatase | Visible-light-triggered release of ampicillin |
| [ | NaYF4:Yb/Tm-TiO2 (sphere-shaped) (20–40 nm) | TiO2 NPs prepared by solvothermal method from tetrabutyl titanate; trifluoroacetates of lantanides were mixed with TiO2 NPs and thermally treated; further functionalization included PEGylation, silylation and conjugation of folic acid | PDT with doxorubicin delivery tested on drug-resistant breast cancers |
| [ | UCNPs@mSiO2/TiO2 (30 nm of silica/titania shell thickness) | silica coating was synthesized on UCNPs with tetraethylorthosilicate, silylated and reacted with tetrabutyl titanate followed by calcination to yield anatase phase | PDT mixed with doxorubicin delivery against HeLa cells) |
| [ | TiO2 (anatase, 10 nm) | TiO2 from butyl titanate by solvothermal method; Au-TiO2 by solvothermal method using mixture of butyl titanate and HAuCl4; both were followed by calcination. | PDT and doxorubicin delivery tested on breast cancer cells |
Synthesis, physicochemical characteristics and applications of selected TiO2 NPs in dentistry, surgery and pharmacy.
| Ref. | Shape of Nanoparticles (Characteristics) | Method of Synthesis | Medical/Biological Use |
|---|---|---|---|
| [ | TiO2 (anatase, 25 nm) | commercial distribution of TiO2 anatase powder was mixed with silver nitrate, reduced and heated at 300 °C | toxicity reduction of teeth whitening gels |
| [ | TiO2 (anatase, ≤15 µm) | undefined/commercial distribution of TiO2, eggshell powder with TiO2 was ground in ball mill | occluding opened dentine tubules |
| [ | TiO2 (anatase, 10 nm) | undefined/commercial distribution | improving of endoprotheses biocompatibility |
| [ | P25 (anatase/rutile 8:2, 21 nm) | commercial distribution | photocatalytic degradation of phenol |
| [ | TiO2 (anatase, 20–50 nm) | commercial distribution | photocatalytic degradation of atenolol |